Frequency Competitors

Stocks . USA . 
Stock . Frequency Therapeutics
KRRO Stock   10.73  0.22  2.09%   
Frequency Therapeutics competes with EnGene Holdings, Altimmune, Annexon, DBV Technologies, and Larimar Therapeutics; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Frequency Therapeutics competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Frequency Therapeutics to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Frequency Therapeutics Correlation with its peers.
To learn how to invest in Frequency Stock, please use our How to Invest in Frequency Therapeutics guide.

Frequency Therapeutics vs LB Pharmaceuticals Correlation

Very good diversification

The correlation between Frequency Therapeutics and LBRX is -0.5 (i.e., Very good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Frequency Therapeutics and LBRX in the same portfolio, assuming nothing else is changed.

Moving together with Frequency Stock

  0.63DRMA Dermata Therapeutics TrendingPairCorr

Moving against Frequency Stock

  0.63DMAC DiaMedica TherapeuticsPairCorr
  0.43FBIO Fortress BiotechPairCorr
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.5410.7322.11
Details
Intrinsic
Valuation
LowRealHigh
0.5210.3021.68
Details
Naive
Forecast
LowNextHigh
5.6717.0428.42
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
7.108.7910.48
Details

Frequency Therapeutics Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Frequency Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Frequency and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Frequency Therapeutics does not affect the price movement of the other competitor.

High positive correlations

LBRX
+ 0.84
ANNX
LBRX
+ 0.82
DBVT
ANRO
+ 0.79
DBVT
DBVT
+ 0.78
ANNX
ANNX
+ 0.74
ENGN
LBRX
+ 0.73
ANRO
  

High negative correlations

SLN
- 0.77
ANNX
SLN
- 0.63
DBVT
LBRX
- 0.6
SLN
ANRO
- 0.59
AMRN
LBRX
- 0.57
AMRN
SLN
- 0.56
ENGN

Risk-Adjusted Indicators

There is a big difference between Frequency Stock performing well and Frequency Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Frequency Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
ENGN  4.51  0.71  0.16  0.50  4.20 
(5.71)
 11.36 
(6.33)
 61.40 
ALT  3.62  0.63  0.11 (97.03) 4.33 
(4.77)
 9.22 
(4.73)
 33.75 
ANNX  4.27  1.31  0.28 (0.90) 3.31 
(5.52)
 11.30 
(7.54)
 35.10 
DBVT  4.20  0.87  0.16 (0.83) 3.79 
(5.23)
 10.53 
(6.81)
 36.36 
LRMR  3.51 (0.27) 0.00 (0.21) 0.00 
 0.00 
 6.96 
(7.49)
 20.14 
AMRN  2.37 (0.26) 0.00  18.57  0.00 
 0.00 
 4.89 
(4.37)
 21.26 
SLN  2.87 (0.46) 0.00 (0.61) 0.00 
 0.00 
 6.88 
(5.28)
 22.91 
ANRO  4.02  0.55  0.06 (0.35) 5.91 
(3.92)
 7.77 
(8.77)
 30.37 
AURA  2.30 (0.22) 0.00 (0.25) 0.00 
 0.00 
 4.74 
(5.34)
 18.08 
LBRX  3.88  0.59  0.13  2.77  3.58 
(4.71)
 9.38 
(6.59)
 23.59 

Frequency Therapeutics Competitive Analysis

The better you understand Frequency Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Frequency Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Frequency Therapeutics' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
KRRO ENGN ALT ANNX DBVT LRMR AMRN SLN ANRO AURA
 2.09 
 10.73 
Frequency
 6.33 
 11.40 
EnGene
 2.91 
 5.66 
Altimmune
 1.77 
 6.66 
Annexon
 6.81 
 22.87 
DBV
 2.44 
 3.60 
Larimar
 4.37 
 15.55 
Amarin
 4.23 
 5.43 
Silence
 1.20 
 16.41 
Alto
 1.05 
 5.68 
Aura
Market Volatility
(90 Days Market Risk)
Unstable
Moderately volatile
Risky
Moderately volatile
Not too volatile
Very risky
Somewhat reliable
Somewhat reliable
Somewhat reliable
Slightly risky
Market Performance
(90 Days Performance)
Weakest
Fair
Fair
Solid
Good
Weakest
Weakest
Weakest
Mild
Weakest
Odds of Financial Distress
(Probability Of Bankruptcy)
Risky
Low
Small
Low
Low
Low
Low
High
Low
Small
Current Valuation
(Equity Enterprise Value)
Fairly Valued
Over Valued
Over Valued
Under Valued
Under Valued
Over Valued
Over Valued
Under Valued
Under Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Strong Hold
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Hold
Sell
Strong Sell
Sell
Current Ratio
N/A
N/A
14.12
8.95
8.54
7.35
2.39
3.76
N/A
21.97
Net Asset
226.24 M
221.47 M
139.31 M
350.07 M
65.66 M
200.22 M
685.35 M
202.63 M
177.54 M
182.5 M
Profit Margin
N/A
N/A
N/A
N/A
N/A
N/A
-0.38
-2.5
N/A
N/A
EBITDA
(88.34 M)
(113.8 M)
(94.81 M)
(134.75 M)
(110.99 M)
(90.57 M)
(74.18 M)
(48.99 M)
(68.61 M)
(94.89 M)
Operating Margin
-17.65
N/A
N/A
N/A
-12.36
N/A
-0.0342
-148.81
N/A
N/A
Current Valuation
53.24 M
653.26 M
379.01 M
848.82 M
1.3 B
135.52 M
58.23 M
110.54 M
405.72 M
216.59 M
Price To Book
1.02
4.86
3.09
6.26
25.21
2.21
0.74
3.62
4.63
2.3
Retained Earnings
(266.59 M)
(372.03 M)
(561.39 M)
(710.7 M)
(286.38 M)
(269.16 M)
(1.67 B)
(474.04 M)
(138.4 M)
(374.23 M)
Current Asset
N/A
N/A
13.9 M
N/A
334.89 M
N/A
143.52 M
N/A
N/A
N/A
One Year Return
N/A
4.07
-6.49
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Beta
2.53
-0.28
0.03
1.19
-0.41
1.06
0.73
1.34
N/A
0.46
Number Of Employees
87
81
59
99
117
65
275
116
76
106
Equity Positions Weight
N/A
N/A
21.57
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Shares Outstanding
9.42 M
66.98 M
104.34 M
149.06 M
54.29 M
83.09 M
20.79 M
47.23 M
31.07 M
63.5 M
Three Year Return
N/A
3.14
-0.57
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cash Flow From Operations
(60.07 M)
(99.24 M)
(79.85 M)
(118.01 M)
(104.47 M)
(70.76 M)
(31.02 M)
(67.64 M)
(47.42 M)
(79.81 M)
Total Debt
44.77 M
31.8 M
1.68 M
28.97 M
7.8 M
5.12 M
7.72 M
117 K
16.94 M
18.77 M
Return On Equity
-0.63
-0.53
-0.53
-0.84
-2.34
-0.78
-0.17
-0.64
-0.45
-0.64
Bond Positions Weight
N/A
97.03
15.26
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Return On Asset
-0.29
-0.29
-0.31
-0.45
-0.77
-0.43
-0.0246
-0.23
-0.24
-0.36
Number Of Shares Shorted
1.11 M
1.5 M
25.81 M
16.28 M
891.49 K
8.24 M
412.53 K
1.26 M
2.2 M
3.17 M
Book Value Per Share
10.54
3.22
1.94
1.4
0.39
1.62
22.06
1.57
4.11
2.49
Current Liabilities
N/A
N/A
10.49 M
N/A
16.02 M
N/A
50.72 M
N/A
N/A
N/A
Total Asset
226.24 M
221.47 M
139.31 M
350.07 M
65.66 M
200.22 M
685.35 M
202.63 M
177.54 M
182.5 M
Short Ratio
3.36
5.52
5.49
5.83
1.2
6.41
4.38
3.43
5.2
17.67
Target Price
8.67
23.5
17.75
14.33
40.42
14.67
12.0
33.8
31.13
19.4
Debt To Equity
N/A
N/A
0.006
0.2
0.016
0.11
0.018
0.022
N/A
0.005
Shares Owned By Institutions
93.85
77.91
40.25
79.5
13.05
98.9
20.27
41.99
65.72
84.36
Market Capitalization
101.05 M
815.2 M
573.88 M
1.01 B
1.33 B
315.83 M
338.09 M
326.86 M
516.01 M
360.7 M
Price To Earning
N/A
N/A
-1.66
N/A
-8.25
N/A
590.0
N/A
N/A
N/A
Price To Earnings To Growth
N/A
N/A
N/A
-0.04
N/A
N/A
-1.74
N/A
N/A
N/A
Price To Sales
13.71
N/A
28694.16
N/A
242.16
N/A
1.49
10.37
N/A
N/A
Net Income
(83.58 M)
(117.3 M)
(95.06 M)
(138.2 M)
(113.92 M)
(80.6 M)
(82.18 M)
(36.19 M)
(61.43 M)
(86.92 M)
Earnings Per Share
-9.42
-2.29
-1.07
-1.41
-5.2
-1.96
-4.2
-1.35
-2.3
-1.91
Shares Owned By Insiders
6.15
0.09
0.65
0.33
N/A
1.1
1.93
24.37
6.43
1.87
Revenue
2.27 M
N/A
20 K
N/A
2.57 M
N/A
228.61 M
43.26 M
N/A
N/A
Year To Date Return
N/A
-0.98
1.67
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Working Capital
116.57 M
169.41 M
126.79 M
285.95 M
13.25 M
170.95 M
415.45 M
170.54 M
159.33 M
145.71 M
Cash And Equivalents
N/A
N/A
184.76 M
177.59 M
247.97 M
54.92 M
303.7 M
51.56 M
N/A
122.13 M
Cash Per Share
N/A
N/A
3.81
3.73
1.32
3.1
0.75
1.72
N/A
4.17
Gross Profit
46 K
N/A
(67.78 M)
N/A
5.5 M
N/A
124.61 M
23.59 M
N/A
N/A
Day Typical Price
10.47
11.65
5.51
6.61
23.27
3.56
15.71
5.66
16.5
5.66
Accumulation Distribution
28086.52
41296.14
486556.0
83779.86
24640.49
178727.0
4030.49
31425.78
9607.45
0.045
Market Facilitation Index
0.0
0.0
N/A
N/A
0.0
N/A
0.0
0.0
0.0
0.26
Daily Balance Of Power
0.2366
(0.88)
0.32
(0.36)
(1.11)
(0.45)
(0.97)
(0.34)
(0.20)
(0.23)
Period Momentum Indicator
0.22
(0.77)
0.16
(0.12)
(1.67)
(0.09)
(0.71)
(0.24)
(0.20)
(0.06)
Rate Of Daily Change
1.02
0.94
1.03
0.98
0.93
0.98
0.96
0.96
0.99
0.99
Day Median Price
10.35
11.77
5.44
6.59
23.47
3.54
15.8
5.78
16.54
5.65
Price Action Indicator
0.5
(0.75)
0.3
0.015
(1.43)
0.015
(0.60)
(0.47)
(0.23)
N/A
Relative Strength Index
35.36
64.26
65.67
64.99
60.79
48.06
49.2
41.2
50.83
49.16
Coefficient Of Variation
(1,472)
924.91
858.5
479.3
785.06
(2,456)
(1,496)
(995.16)
1226.32
(2,099)
Mean Deviation
5.26
4.51
3.62
4.27
4.2
3.51
2.37
2.87
4.02
2.3
Jensen Alpha
(0.69)
0.7088
0.6312
1.31
0.8692
(0.27)
(0.26)
(0.46)
0.551
(0.22)
Total Risk Alpha
(1.88)
0.0785
0.0989
0.6483
0.1854
(0.66)
(0.62)
(0.80)
(0.1)
(0.49)
Sortino Ratio
N/A
0.1607
0.1129
0.2808
0.1644
N/A
N/A
N/A
0.057
N/A
Downside Variance
N/A
22.12
24.58
16.65
19.71
N/A
N/A
N/A
46.18
N/A
Standard Deviation
11.38
7.74
5.5
5.88
6.37
4.73
3.74
3.99
5.74
3.31
Kurtosis
38.15
19.67
5.94
4.77
4.68
1.39
7.74
1.81
2.38
2.51
Potential Upside
10.98
11.36
9.22
11.3
10.53
6.96
4.89
6.88
7.77
4.74
Treynor Ratio
0.6291
0.4968
(97.03)
(0.90)
(0.83)
(0.21)
18.57
(0.61)
(0.35)
(0.25)
Maximum Drawdown
91.55
61.4
33.75
35.1
36.36
20.14
21.26
22.91
30.37
18.08
Variance
129.41
59.91
30.25
34.58
40.53
22.38
13.99
15.89
32.97
10.94
Market Risk Adjusted Performance
0.6391
0.5068
(97.02)
(0.89)
(0.82)
(0.20)
18.58
(0.60)
(0.34)
(0.24)
Risk Adjusted Performance
(0.04)
0.0884
0.0941
0.1619
0.1023
(0.02)
(0.04)
(0.07)
0.0686
(0.03)
Skewness
(5.44)
3.47
(0.30)
1.48
1.64
(0.41)
1.13
0.4889
(0.75)
0.9654
Semi Deviation
N/A
4.2
4.33
3.31
3.79
N/A
N/A
N/A
5.91
N/A
Information Ratio
(0.08)
0.0977
0.1018
0.1949
0.1147
(0.06)
(0.09)
(0.12)
0.0674
(0.07)
Value At Risk
(6.62)
(6.33)
(4.73)
(7.54)
(6.81)
(7.49)
(4.37)
(5.28)
(8.77)
(5.34)
Expected Short fall
N/A
(5.71)
(4.77)
(5.52)
(5.23)
N/A
N/A
N/A
(3.92)
N/A
Downside Deviation
N/A
4.7
4.96
4.08
4.44
N/A
N/A
N/A
6.8
N/A
Semi Variance
N/A
17.61
18.77
10.97
14.4
N/A
N/A
N/A
34.95
N/A

Frequency Therapeutics Competition Performance Charts

Five steps to successful analysis of Frequency Therapeutics Competition

Frequency Therapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Frequency Therapeutics in relation to its competition. Frequency Therapeutics' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Frequency Therapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Frequency Therapeutics' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Frequency Therapeutics, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Frequency Therapeutics position

In addition to having Frequency Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Military Industrial Thematic Idea Now

Military Industrial
Military Industrial Theme
A collection of large United States defense contractors including companies involved in production or distribution of aircraft, ships, vehicles, weaponry, and electronic systems in cooperation with the government. The Military Industrial theme has 33 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Military Industrial Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Frequency Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Frequency Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Frequency Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Frequency Therapeutics Stock:
How To Invest In Frequency
Details
Is Frequency Stock a good investment?
Details
What is Frequency Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out Frequency Therapeutics Correlation with its peers.
To learn how to invest in Frequency Stock, please use our How to Invest in Frequency Therapeutics guide.
You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Frequency Therapeutics. If investors know Frequency will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Frequency Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Frequency Therapeutics is measured differently than its book value, which is the value of Frequency that is recorded on the company's balance sheet. Investors also form their own opinion of Frequency Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Frequency Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Frequency Therapeutics' market value can be influenced by many factors that don't directly affect Frequency Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
Please note, there is a significant difference between Frequency Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Frequency Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Frequency Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY